AMPE Ampio Pharmaceuticals, Inc.

0.59
+0  (5%)
Previous Close 0.56
Open 0.56
Price To book 4.85
Market Cap 33.81M
Shares 57,242,000
Volume 163,923
Short Ratio 23.83
Av. Daily Volume 239,197

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint - June 2016. Noted February 27, 2017 that a further pre-approval trial is required - to be completed concurrently with preparation for BLA filing.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema